Empagliflozin as Add-On Therapy for Type 2 Diabetes

Introduction to Empagliflozin

The American College of Physicians strongly recommends SGLT-2 inhibitors like empagliflozin as the preferred second-line therapy after metformin for patients with type 2 diabetes, due to their proven benefits in reducing mortality, cardiovascular events, and kidney disease progression 1, 3
Empagliflozin is specifically recommended in patients with type 2 diabetes to reduce cardiovascular events and the risk of death, as stated by the European Heart Journal 2

Empagliflozin provides significant benefits beyond glycemic control, including reduction in all-cause mortality, major adverse cardiovascular events (MACE), progression of chronic kidney disease, and hospitalization due to heart failure, as recommended by the American College of Physicians and other major guidelines 1, 3
The American College of Physicians specifically recommends against adding DPP-4 inhibitors like sitagliptin to metformin for reducing morbidity and mortality, citing strong recommendation and high-certainty evidence 1

Monitor renal function (eGFR) at least annually, with increased frequency to every 3-6 months if eGFR falls below 60 ml/min/1.73 m², as recommended by Kidney International 4
Empagliflozin can be initiated in patients with eGFR ≥20 ml/min/1.73 m², according to Annals of Internal Medicine and Kidney International 4, 5

Target HbA1c levels between 7% and 8% for most adults with type 2 diabetes, as recommended by the American College of Physicians and other major guidelines 1, 3
Evaluate response after approximately 3 months of therapy, and consider increasing the dose of empagliflozin or adding a third agent if glycemic targets are not achieved, as stated by Diabetes Care and Annals of Internal Medicine 5, 6